Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples

ObjectiveTo evaluate in HIV-1 the extent of phenotypic and genotypic antiretroviral drug resistance and cross-resistance towards the protease inhibitors (PIs) saquinavir, ritonavir, indinavir and nelfinavir among a set of patient samples originating from European and US routine clinical practice and submitted for phenotypic drug resistance testing and/or genotypic analysis. The mutational pattern(s) underlying both resistance and cross-resistance to PIs was investigated. MethodOver 6000 patient isolates with plasma viral load greater than 1000 copies/ml plasma were analysed. Phenotypic resistance was evaluated by a recombinant virus assay. Phenotypic resistance is expressed as the fold-increase of the 50% inhibitory concentration (IC50) value of a compound for a patient-derived recombinant virus isolate compared with that for a wild-type laboratory virus. Genotypic analysis is reported as amino acid changes at positions in the HIV-1 protease compared to a wild-type reference. ResultsPhenotypic resistance to any single PI was observed in 17 to 25% of the clinical isolates investigated. Phenotypic cross-resistance among PIs (> 10-fold increase in IC50 value) was detected in 59 to 80% of the samples resistant (> 10-fold increase in IC50 value) to at least one PI. The prevalent mutations in PI-resistant isolates involved substitutions at codons 10, 36, 46, 54, 71, 77, 82 and 90. The most frequent mutational pattern in samples with PI cross-resistance involved combined substitutions at positions 10 and 90, extended with substitutions at positions 54, 71, 77, 82 or 84. ConclusionsExtensive use of first-generation PIs leads to the emergence of HIV-1 isolates possessing cross-resistance to all members of this class. Identification of particular mutational profiles among these isolates may assist in the design of new generation inhibitors with specific activity against protease-mutant HIV strains.

[1]  J. Falloon,et al.  Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites , 1997, Journal of virology.

[2]  B. Larder,et al.  Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates , 1994, Antimicrobial Agents and Chemotherapy.

[3]  P. Harrigan,et al.  Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting. , 1999, AIDS.

[4]  T. Merigan,et al.  Multiple Concurrent Reverse Transcriptase and Protease Mutations and Multidrug Resistance of HIV-1 Isolates from Heavily Treated Patients , 1998, Annals of Internal Medicine.

[5]  J. Condra,et al.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors , 1995, Nature.

[6]  M. Markowitz,et al.  Resistance to Human Immunodeficiency Virus Type 1 Protease Inhibitors , 1998, Antimicrobial Agents and Chemotherapy.

[7]  B. Larder,et al.  Mutations in Retroviral Genes Associated with Drug Resistance , 1996 .

[8]  D. Ho,et al.  Ordered accumulation of mutations in HIV protease confers resistance to ritonavir , 1996, Nature Medicine.

[9]  H. Vahaboğlu,et al.  Activities of cefepime and five other antibiotics against nosocomial PER-1-type and/or OXA-10-type beta-lactamase-producing Pseudomonas aeruginosa and Acinetobacter spp. , 1998, The Journal of antimicrobial chemotherapy.

[10]  C. Debouck,et al.  The HIV-1 protease as a therapeutic target for AIDS. , 1992, AIDS research and human retroviruses.

[11]  G. Moyle,et al.  The role of combinations of HIV protease inhibitors in the management of persons with HIV infection. , 1998, Expert opinion on investigational drugs.

[12]  W. Greene,et al.  The molecular biology of human immunodeficiency virus type 1 infection. , 1991, The New England journal of medicine.

[13]  R. Hogg,et al.  The antiviral effect of ritonavir and saquinavir incombination amongst HIV‐infected adults: results from a community‐based study , 1998, AIDS.

[14]  Brendan Larder,et al.  A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs , 1998, Antimicrobial Agents and Chemotherapy.

[15]  S. Hammer,et al.  Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. , 1997, JAMA.

[16]  D. R. Kuritzkes,et al.  Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from Patients Treated with the Protease Inhibitor Nelfinavir , 1998, Antimicrobial Agents and Chemotherapy.

[17]  J. Mellors,et al.  Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor , 1996, Journal of virology.

[18]  J. Weber,et al.  Emergence of resistant variants of HIV in vivo during monotherapy with the proteinase inhibitor saquinavir. , 1997, The Journal of antimicrobial chemotherapy.

[19]  D. Ho,et al.  Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease , 1996, Antimicrobial agents and chemotherapy.